These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 8672908)

  • 1. [GnRH antagonists in gynecology: initial results within the scope of controlled ovarian hyperstimulation].
    Felberbaum R; Reissmann T; Zoll C; Küpker W; al-Hasani S; Diedrich C; Diedrich K
    Gynakol Geburtshilfliche Rundsch; 1995; 35 Suppl 1():113-7. PubMed ID: 8672908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation.
    Albano C; Smitz J; Camus M; Riethmüller-Winzen H; Van Steirteghem A; Devroey P
    Fertil Steril; 1997 May; 67(5):917-22. PubMed ID: 9130900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preserved pituitary response under ovarian stimulation with HMG and GnRH antagonists (Cetrorelix) in women with tubal infertility.
    Felberbaum RE; Reissmann T; Küpker W; Bauer O; al Hasani S; Diedrich C; Diedrich K
    Eur J Obstet Gynecol Reprod Biol; 1995 Aug; 61(2):151-5. PubMed ID: 7556837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin).
    Olivennes F; Belaisch-Allart J; Emperaire JC; Dechaud H; Alvarez S; Moreau L; Nicollet B; Zorn JR; Bouchard P; Frydman R
    Fertil Steril; 2000 Feb; 73(2):314-20. PubMed ID: 10685535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preliminary report on the effect of a lower dose of gonadotropin-releasing hormone antagonist (cetrorelix) on ovarian hyperstimulation in lower-weight Asian women.
    Chang YL; Hsieh YY; Tsai HD
    Taiwan J Obstet Gynecol; 2006 Dec; 45(4):317-20. PubMed ID: 17175489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Suppression of endogenous LH increase in ovarian stimulation with the GnRH antagonist Cetrorelix].
    Diedrich K; Diedrich C; Santos E; Bauer O; Zoll C; al-Hasani S; Reissmann T; Krebs D; Klingmüller D
    Geburtshilfe Frauenheilkd; 1994 Apr; 54(4):237-40. PubMed ID: 8013860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subtle progesterone rise in the single-dose gonadotropin-releasing hormone antagonist (cetrorelix) stimulation protocol in patients undergoing in vitro fertilization or intracytoplasmic sperm injection cycles.
    Seow KM; Lin YH; Huang LW; Hsieh BC; Huang SC; Chen CY; Chen PH; Tzeng CR; Hwang JL
    Gynecol Endocrinol; 2007 Jun; 23(6):338-42. PubMed ID: 17616858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mg.
    Olivennes F; Alvarez S; Bouchard P; Fanchin R; Salat-Baroux J; Frydman R
    Hum Reprod; 1998 Sep; 13(9):2411-4. PubMed ID: 9806259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of gonadotrophin-releasing hormone (GnRH) antagonist during the LH surge in normal women and during controlled ovarian hyperstimulation.
    Christin-Maitre S; Olivennes F; Dubourdieu S; Chabbert-Buffet N; Charbonnel B; Frydman R; Bouchard P
    Clin Endocrinol (Oxf); 2000 Jun; 52(6):721-6. PubMed ID: 10848876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization.
    Hsieh YY; Chang CC; Tsai HD
    Taiwan J Obstet Gynecol; 2008 Mar; 47(1):66-74. PubMed ID: 18400585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the GnRH antagonist cetrorelix according to the multiple dose protocol: a prospective uncontrolled phase III study.
    Felberbaum RE; Albano C; Ludwig M; Riethmüller-Winzen H; Grigat M; Devroey P; Diedrich K
    Hum Reprod; 2000 May; 15(5):1015-20. PubMed ID: 10783344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation.
    Diedrich K; Diedrich C; Santos E; Zoll C; al-Hasani S; Reissmann T; Krebs D; Klingmüller D
    Hum Reprod; 1994 May; 9(5):788-91. PubMed ID: 7929723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of gonadotropin-releasing hormone antagonists in in vitro fertilization.
    Diedrich K; Ludwig M; Felberbaum RE
    Semin Reprod Med; 2001 Sep; 19(3):213-20. PubMed ID: 11679902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Revisiting the clomifene-gonadotropin protocol in IVF with the use of a GnRH antagonist].
    Emperaire JC; Parneix I; Perraguin-Jayot S
    Gynecol Obstet Fertil; 2003 Nov; 31(11):927-31. PubMed ID: 14623556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy of the gonadotropin-releasing hormone antagonist, ganirelix, in Korean women undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer with recombinant follicle-stimulating hormone.
    Moon SY; Ku SY; Kim SM; Jee BC; Suh CS; Choi YM; Kim JG; Kim SH
    J Obstet Gynaecol Res; 2005 Jun; 31(3):227-35. PubMed ID: 15916659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of LH serum concentration on the clinical outcome of IVF cycles in patients receiving two regimens of clomiphene citrate/gonadotrophin/0.25 mg cetrorelix.
    Tavaniotou A; Albano C; Van Steirteghem A; Devroey P
    Reprod Biomed Online; 2003 Jun; 6(4):421-6. PubMed ID: 12831586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol.
    Griesinger G; Schultze-Mosgau A; Dafopoulos K; Schroeder A; Schroer A; von Otte S; Hornung D; Diedrich K; Felberbaum R
    Hum Reprod; 2005 May; 20(5):1200-6. PubMed ID: 15665010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro fertilization outcomes in patients experiencing a premature rise in luteinizing hormone during a gonadotropin-releasing hormone antagonist cycle.
    Kummer NE; Weitzman VN; Benadiva CA; Schmidt DW; Engmann LL; Nulsen JC
    Fertil Steril; 2011 Jun; 95(8):2592-4. PubMed ID: 21292260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of coasting in patients undergoing controlled ovarian stimulation with the gonadotropin-releasing hormone antagonist cetrorelix.
    Bahceci M; Ulug U; Tosun S; Erden HF; Bayazit N
    Fertil Steril; 2006 May; 85(5):1523-5. PubMed ID: 16566935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane-35 pre-treatment for patients with polycystic ovary syndrome: a prospective randomized study.
    Hwang JL; Seow KM; Lin YH; Huang LW; Hsieh BC; Tsai YL; Wu GJ; Huang SC; Chen CY; Chen PH; Tzeng CR
    Hum Reprod; 2004 Sep; 19(9):1993-2000. PubMed ID: 15284212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.